Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 10/20 | 0.49 |
| ▸ | CA1 | P00915 | 8/20 | 0.49 |
| ▸ | CA12 | O43570 | 8/20 | 0.49 |
| ▸ | CA9 | Q16790 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059759 | 0.84 | CA2 (0.50) | L3MBTL1MAPTNPC1CA2CA1 | |
| SCHEMBL7011722 | 0.83 | MAPT (0.50) | L3MBTL1MAPTMEN1NPC1RAB9A | |
| SCHEMBL6867989 | 0.83 | MAPT (0.50) | L3MBTL1MAPTMEN1NPC1RAB9A | |
| SCHEMBL25284343 | 0.82 | MAPT (0.47) | L3MBTL1MAPTMEN1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL11538427 | 0.81 | KEAP1 (0.52) | L3MBTL1MAPTNPC1CA2CA1 | |
| SCHEMBL31527700 | 0.81 | KEAP1 (0.52) | L3MBTL1MAPTNPC1CA2CA1 | |
| SCHEMBL14900132 | 0.80 | MAPT (0.44) | L3MBTL1MAPTMEN1NPC1RAB9A | |
| SCHEMBL4261189 | 0.79 | HTR6 (0.67) | CA2CA1CA12CA9LMNA | |
| SCHEMBL30564805 | 0.79 | MAPT (0.47) | L3MBTL1MAPTMEN1NPC1RAB9A | |
| SCHEMBL10942684 | 0.79 | MAPT (0.59) | L3MBTL1MAPTMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | claimed |
| US-12559455-B2 | Compound as a UBR box domain ligand | AUTOTAC INC. (KR) | 2026-02-24 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| EP-3174868-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | Nuevolution A/S (DK) | 2017-06-07 | — | — | EP | disclosed |
| US-9409909-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2016016316-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2016-02-04 | — | — | WO | disclosed |
| US-8835468-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-7776877-B2 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-6617357-B2 | Administering to a patient for inhibiting cyclic nucleotide phosphodiesterases (PDEs) activity, a benzenesulfonamide compound | SMITHKLINE BEECHAM CORPORATION | 2003-09-09 | — | — | US | disclosed |
| US-20020156064-A1 | Compounds and their use as PDE inhibitors | SMITHKLINE BEECHAM CORP | 2002-10-24 | — | — | US | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CCR9, CCR2, CCR10 | L3MBTL1 3262/4885MAPT 4750/4885MEN1 4798/4885 |
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CCR9, CCR2, CCR10 | L3MBTL1 3262/4885MAPT 4750/4885MEN1 4798/4885 |
| US-20020156064-A1 | Compounds and their use as PDE inhibitors | PDE3A, PDE2A, PDE5A | L3MBTL1 4316/4885MAPT 2761/4885MEN1 2589/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | L3MBTL1 2377/4885MAPT 4415/4885MEN1 4867/4885 |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | L3MBTL1 1141/4885MAPT 235/4885MEN1 3583/4885 |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CCR9, CCR1, CCR2 | L3MBTL1 3008/4885MAPT 3899/4885MEN1 4848/4885 |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | L3MBTL1 2388/4885MAPT 575/4885MEN1 3579/4885 |
| US-12559455-B2 | Compound as a UBR box domain ligand | UBR4, UBTF, UBQLN1 | L3MBTL1 1436/4885MAPT 1338/4885MEN1 4497/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | L3MBTL1 2388/4885MAPT 575/4885MEN1 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.